About Ultraceuticals & Fortem Biosciences
Welcome to Ultraceuticals, a visionary endeavor by Fortem Biosciences Pvt. Ltd., where innovation meets healthcare. Nestled in the tech hub of Bangalore, India, we are an interdisciplinary neo-biotech enterprise dedicated to transforming the preclinical landscape of drug discovery, repurposing, and solid-state formulation.
Pioneering the Future of Healthcare Through Computational Biology
Our mission is to bring affordable, high-efficacy medicines to global markets by reducing development timelines and costs while maintaining the highest standards of accuracy. We bridge the gap between advanced deep learning and practical healthcare solutions, accelerating the development of effective treatments for chronic, metabolic, and neurodegenerative diseases.
Global Leadership in AI-Driven Drug Discovery & Formulation
We envision a future where our AI-first pharmaceutical operating system becomes a cornerstone in the development of new, life-saving medications worldwide. Creating a more sustainable, ethical, and accessible approach to drug development that promotes global well-being, inclusivity, and scientific excellence.
Four Years of Scientific Maturation
From founding algorithms to full-stack pharmaceutical intelligence. Fortem Biosciences has systematically de-risked every phase of the drug discovery, repurposing, and formulation lifecycle.
Incorporation & 1.8M-Node Interactome Knowledge Graph
Fortem Biosciences Pvt. Ltd. was legally incorporated in Bengaluru in June 2022, co-founding ULTRACEUTICALS with an algorithmic mandate. Initiated the construction of the human interactome heterogeneous knowledge graph (1.8M nodes, 42M biological edges) for deeptech computational biology.
DiscoveraAI Discovery Engine & Peer-Reviewed Research
Launched DiscoveraAI generative chemistry and DynaDock microsecond molecular dynamics suite. Published peer-reviewed research in Nutrients (Aug 2023, 15(17):3751) on oat avenanthramides and PI3K signaling in neurodegeneration with international university collaborators.
ReviveAI (SCALEX) Repurposing & Second Peer-Reviewed Paper
Deployed ReviveAI (SCALEX) enterprise drug repurposing using node-level contrastive GNNs with modality dropout defense. Published peer-reviewed research in Life (Apr 2024, 14(4):504) validating tangeretin for neuroinflammation-mediated neurodegeneration with JSS AHER & Sejong University.
Dossier360 Regulatory Swarms & Razorpay National Spotlight
Engineered Dossier360 multi-agent regulatory due-diligence intelligence for Orange/Purple book patent thicket triaging and bioequivalence risk automation. Featured nationally in Razorpay Rize's 'Backing India's Boldest' spotlight.
Enformis CMC AI, Razorpay Next Big Thing & AI CRO Repositioning
Launched Enformis predictive solid-state formulation AI (Tonset ±3.8°C across 106 validated APIs). Featured in Razorpay's 'Next Big Thing' Sketchpad episode and Bengaluru billboard. Formally repositioned as an AI-first CRO services model with proprietary computational software kept internal.
Our Cultural & Engineering Principles
The foundational standards that define Fortem Biosciences & Ultraceuticals.
Quality is Our Habit
“We have made quality our habit. It’s not something that we just strive for - we live by this principle every day.” Every predictive algorithm, molecular simulation, and formulation kinetic model is rigorously benchmarked against gold-standard wet-lab assays.
Engineering at Computational Scale
Bridging novel drug design and generic medicines with cutting-edge AI - delivering the accuracy, scale, and scientific trust global pharma demands across de novo discovery, repurposing, and formulation.
Preemptive Formulation Intelligence
Solving the 90% formulation failure rate before wet-lab compounding. Enformis models thermal onset degradation, crystal habits, and excipient synergy at the earliest in silico stages.
Zero Trust & HIPAA Air-Gapping
Client-nominated biological targets, proprietary chemical matter, and genomic data are protected under strict Zero Trust Architecture with 100% offline air-gapping and mutual NDA terms.
Driven by World-Class Scientists, AI Researchers & Clinicians
Meet the founders, deep learning architects, organic medicinal chemists, and medical advisors turning biopharmaceutical possibilities into verified clinical leads.
Executive Leadership & Founders
Prathamesh Walse
Co-Founder & Head of Science and Technology Development at ULTRACEUTICALS / Fortem Biosciences (Jun 2022 – Present). Leads the architectural design and execution of our AI drug discovery platforms (DiscoveraAI, ReviveAI, Enformis, Dossier360). Directs the AI drug discovery pipeline spanning machine learning target identification, ADMET profiling, and mechanism elucidation. Oversees cross-functional teams of bioinformaticians, data scientists, and full-stack engineers, driving collaborative validation studies with global research institutions. Co-author of peer-reviewed neurodegeneration studies in Nutrients (2023) and Life (2024).
Ankush Jamadagni
Co-Founder at ULTRACEUTICALS / Fortem Biosciences Pvt. Ltd. (Jun 2022 – Present). Bringing cross-functional leadership across biotechnology commercialization, biopharma strategy, and enterprise partnerships. Co-author of peer-reviewed research papers under Fortem Biosciences in Nutrients (2023) and Life (2024). Former leadership experience across Infosys, PUMA, and Mylan.
Core Technology & AI Architecture Team
Core Scientific & Chemical Discovery Team
Dr. Nirupma Jadon (Singh)
PhD in Chemistry. Serving as Scientific Consultant with deep expertise in organic synthesis, active compound formulation, excipient stability, and antimicrobial evaluation.
Amardeep Singh
M.Sc. Eng. in Chemical Engineering & Applied Chemistry. Bridging molecular dynamics forcefields with deep learning surrogate models.
Dr. Madhuri Pola
Academic prowess in structure-based drug design, multi-omics bioinformatics, biotechnology, and high-yield bioprocess optimization.
Scientific & Clinical Advisory Board
Dr. Soumya Ghosh
Advising on institutional, national, and international research translation grants (DBT, BIRAC, and global health foundations).
Dr. Ravindra Kumar
Assistant Professor at National Institute of Technology (NIT) Calicut. Guiding computational biophysics and macromolecular modeling.
Dr. Megha Rao
Guiding clinical progression protocols, patient safety endpoints, and therapeutic interchangeability across candidate drug classes.
Dr. Archa Prasad
Shaping clinical trial protocols, GCP compliance, and international regulatory dossier submissions to FDA and EMA benchmarks.
Dr. KV Ganapathy
Advising on patient-centric due diligence, formulation bioavailability, and bioequivalence validation pathways.
Peer-Reviewed Publications & Research Collaborations
Our computational platforms and preclinical hypotheses are backed by published international research co-authored under Fortem Biosciences with global research faculties.
Oat Avenanthramides and PI3K/Akt Signaling Kinetics in Neurodegeneration
Peer-reviewed review investigating molecular mechanisms, neuroprotective pathway modulation, and in silico target affinity of oat-derived polyphenolic alkaloids. Co-authored under Fortem Biosciences affiliation.
Tangeretin Polymethoxyflavones in Neuroinflammation-Mediated Neurodegenerative Therapeutics
Comprehensive evaluation of citrus-derived bioflavonoids across microglial repolarization, blood-brain barrier permeability, and neuroinflammatory cascade suppression.
National Deeptech Spotlight: Razorpay Rize & Next Big Thing
ULTRACEUTICALS has been featured in Razorpay Rize’s national “Backing India’s Boldest” initiative (May 2025), spotlighted on Razorpay’s “Next Big Thing” Sketchpad episode (June 2026), and showcased on a prominent company billboard outside Razorpay’s Bengaluru headquarters (September 2026), celebrating India’s emergent AI-first biopharmaceutical infrastructure.
Ready to Accelerate Your Preclinical Discovery?
Whether you are an institutional pharma co-developer, biotech venture partner, or academic investigator - our team is ready to accelerate your pipeline.